SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Krifors Anders) "

Sökning: WFRF:(Krifors Anders)

  • Resultat 1-10 av 21
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Krifors, Karin, et al. (författare)
  • I stället för avslutning: Antirasismer som hopp i mörka tider
  • 2024
  • Ingår i: Antirasismer och antirasister: : Realistiska utopier, spänningar och vardagserfarenheter. - Realistiska utopier, spänningar och vardagserfarenheter.. - 9789174450606 - 9789174451092 ; , s. 485-489
  • Bokkapitel (refereegranskat)
  •  
2.
  • Krifors, Karin, 1982-, et al. (författare)
  • Introduktion: Från rasism till antirasism(er)
  • 2024
  • Ingår i: Antirasismer och antirasister : Realistiska utopier, spänningar och vardagserfarenheter - Realistiska utopier, spänningar och vardagserfarenheter. - Stockholm : Bokförlaget atlas & Kriterium. - 9789174450606 - 9789174451092 ; , s. 8-37
  • Bokkapitel (refereegranskat)
  •  
3.
  • Krifors, Anders, et al. (författare)
  • An experimental porcine model of invasive candidiasis
  • 2023
  • Ingår i: Intensive Care Medicine Experimental. - : Springer Nature. - 2197-425X. ; 11:1
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundInvasive candidiasis (IC) is a severe and often fatal fungal infection that affects critically ill patients. The development of animal models that mimic human disease is essential for advancing our understanding of IC pathophysiology and testing experimental or novel treatments. We aimed to develop a large animal model of IC that could provide a much-needed addition to the widely used murine models.ResultsA total of 25 pigs (including one control), aged between 9 and 12 weeks, with a median weight of 25.1 kg (IQR 24.1–26.2), were used to develop the porcine IC model. We present the setup, the results of the experiments, and the justification for the changes made to the model. The experiments were conducted in an intensive care setting, using clinically relevant anaesthesia, monitoring and interventions. The final model used corticosteroids, repeated Candida inoculation, and continuous endotoxin. The model consistently demonstrated quantifiable growth of Candida in blood and organs. The registered physiological data supported the development of the sepsis-induced circulatory distress observed in IC patients in the ICU.ConclusionsOur proposed porcine model of IC offers a potential new tool in the research of IC.
  •  
4.
  • Antirasismer och antirasister : realistiska utopier, spänningar och vardagserfarenheter
  • 2024. - 1
  • Samlingsverk (redaktörskap) (övrigt vetenskapligt/konstnärligt)abstract
    • I antologin Antirasismer och antirasister: Realistiska utopier, spänningar och vardagserfarenheter utforskar 24 forskare hur motståndet mot olika former av rasism bedrivs och förkroppsligas bedrivs bland grupper av människor som på en mängd sätt, ofta motsägelsefullt, sällan framgångsrikt, men alltid envist och framåtblickande drömmer bortom rasismer. Antologin illustrerar antirasismens bredd, men analyserar också dess problem och svagheter. Inspirerade av bland annat anti-, post- och dekoloniala traditioner tillsammans med sociala rörelseperspektiv utmanar antologin ett statiskt och essentialiserande förhållningssätt som återfinns i forskning och politik och som har en tendens att betona ojämlikhetens stabilitet och oföränderlighet, även när det gäller rasism. Som helhet, utöver en mängd konkreta analyser och beskrivningar av historisk och samtida aktivism, visar de olika författarna också på antirasismernas möjligheter och kan därmed ingjuta ett visst hopp, i dessa mörka tider, för de som vill ha ett samhälle utan rasism.
  •  
5.
  • Brodin, Daniel, et al. (författare)
  • Inhaled ciclesonide in adults hospitalised with COVID-19 : a randomised controlled open-label trial (HALT COVID-19)
  • 2023
  • Ingår i: BMJ Open. - : BMJ Publishing Group Ltd. - 2044-6055. ; 13:2
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To assess the efficacy of inhaled ciclesonide in reducing the duration of oxygen therapy (an indicator of time to clinical improvement) among adults hospitalised with COVID-19.DESIGN: Multicentre, randomised, controlled, open-label trial.SETTING: 9 hospitals (3 academic hospitals and 6 non-academic hospitals) in Sweden between 1 June 2020 and 17 May 2021.PARTICIPANTS: Adults hospitalised with COVID-19 and receiving oxygen therapy.INTERVENTION: Inhaled ciclesonide 320 µg two times a day for 14 days versus standard care.MAIN OUTCOME MEASURES: Primary outcome was duration of oxygen therapy, an indicator of time to clinical improvement. Key secondary outcome was a composite of invasive mechanical ventilation/death.RESULTS: Data from 98 participants were analysed (48 receiving ciclesonide and 50 receiving standard care; median (IQR) age, 59.5 (49-67) years; 67 (68%) men). Median (IQR) duration of oxygen therapy was 5.5 (3-9) days in the ciclesonide group and 4 (2-7) days in the standard care group (HR for termination of oxygen therapy 0.73 (95% CI 0.47 to 1.11), with the upper 95% CI being compatible with a 10% relative reduction in oxygen therapy duration, corresponding to a <1 day absolute reduction in a post-hoc calculation). Three participants in each group died/received invasive mechanical ventilation (HR 0.90 (95% CI 0.15 to 5.32)). The trial was discontinued early due to slow enrolment.CONCLUSIONS: In patients hospitalised with COVID-19 receiving oxygen therapy, this trial ruled out, with 0.95 confidence, a treatment effect of ciclesonide corresponding to more than a 1 day reduction in duration of oxygen therapy. Ciclesonide is unlikely to improve this outcome meaningfully.TRIAL REGISTRATION NUMBER: NCT04381364.
  •  
6.
  • Granstam, Elisabet, 1963-, et al. (författare)
  • No findings of SARS-CoV-2 in conjunctival swabs from patients at an emergency outpatient ophthalmological healthcare facility in a Swedish county hospital : a cross-sectional study
  • 2021
  • Ingår i: BMJ Open Ophthalmology. - : BMJ Publishing Group Ltd. - 2397-3269. ; 6:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background COVID-19 is caused by SARS-CoV-2. Virus has been found in conjunctiva of hospitalised patients with COVID-19. Conjunctivitis has also been reported as a presenting symptom of disease.Objective The aims of the study were to investigate the prevalence of SARS-CoV-2 in the conjunctiva and throat among patients presenting at the emergency outpatient ophthalmological healthcare facility at a county hospital along with investigating the seroprevalence of SARS-CoV-2 among staff at the department.Methods and Analysis Swabs from conjunctiva and throat of patients were analysed with real-time reverse transcriptase PCR (RT-PCR) for SARS-CoV-2. Blood samples for serological analysis were obtained from staff. A questionnaire was used to investigate symptoms associated with COVID-19 during the last 3 months as well as symptoms for which the patients were seeking ophthalmological healthcare.Results In total, 68 patients and 70 individuals from the staff were included in the study. Conjunctivitis was observed in 7% of patients. One patient, presenting with reduced visual acuity due to preretinal haemorrhage in the macula, was positive for SARS-CoV-2 in throat swab. Contact tracing was negative. All other RT-PCR tests were negative. Seropositivity for SARS-CoV-2 was found in 4% of staff.Conclusions Our study demonstrated low prevalence of SARS-CoV-2 among patients as well as low seroprevalence of SARS-CoV-2 IgG-antibodies among staff at the ophthalmological ward. The risk for contracting COVID-19 at the department was small. Follow-up investigation is planned.
  •  
7.
  • Hammarström, Helena, et al. (författare)
  • Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies
  • 2023
  • Ingår i: Clinical Infectious Diseases. - : University of Chicago Press. - 1058-4838 .- 1537-6591. ; 76:3, s. e1252-e1260
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Recent studies have reported that reduced dose trimethoprim-sulfamethoxazole (TMP-SMX) may be effective in the treatment of Pneumocystis jirovecii pneumonia (PJP) but data is lacking for patients with hematologic malignancies.METHODS: This retrospective study included all adult hematologic patients with PJP between 2013 and 2017 at six Swedish University Hospitals. Treatment with 7.5-15 mg TMP/kg/day (reduced dose) was compared with >15-20 mg TMP/kg/day (standard dose), after correction for renal function. The primary outcome was the change in respiratory function (ΔPaO2/FiO2) between baseline and day 8. Secondary outcomes were clinical failure and/or death at day 8 and death at day 30.RESULTS: Out of a total of 113 included patients, 80 patients received reduced dose, and 33 patients received standard dose. The overall 30-day mortality in the whole cohort was 14%. There were no clinically relevant differences in ΔPaO2/FiO2 at day 8 between the treatment groups, neither before nor after controlling for potential confounders in an adjusted regression model (-13,6 mmHg [95% CI -56,7-29,5] and -9,4 mmHg, [95% CI -50.5-31.7], respectively). Clinical failure and/or death at day 8 and 30-day mortality did not differ significantly between the groups, 18% vs. 21% and 14% vs. 15%, respectively. Among patients with mild to moderate pneumonia, defined as PaO2/FiO2>200 mmHg, all 44 patients receiving reduced dose were alive at day 30.CONCLUSION: In this cohort of 113 patients with hematologic malignancies, reduced dose TMP-SMX was effective and safe for treating mild to moderate PJP.
  •  
8.
  • Kolankiewicz, Marta, et al. (författare)
  • Lagen som farmakon – Antirasistiskt engagemang i juridiken
  • 2024
  • Ingår i: Antirasismer och antirasister : Realistiska utopier, spänningar och vardagserfarenheter - Realistiska utopier, spänningar och vardagserfarenheter. - 9789174450606 - 9789174451092 ; , s. 336-359
  • Bokkapitel (refereegranskat)
  •  
9.
  • Krifors, Anders, et al. (författare)
  • Combining T2Bacteria and T2Candida Panels for Diagnosing Intra-Abdominal Infections : A Prospective Multicenter Study
  • 2022
  • Ingår i: Journal of Fungi. - : MDPI. - 2309-608X. ; 8:8
  • Tidskriftsartikel (refereegranskat)abstract
    • The T2Bacteria panel is a direct-from-blood assay that delivers rapid results, targeting E. coli, S. aureus, K. pneumoniae, A. baumanii, P. aeruginosa, and E. faecium (ESKAPE pathogens). In this study, T2Bacteria and T2Candida (targeting C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis) were evaluated in parallel with blood cultures in 101 consecutive surgical patients with suspected intra-abdominal infection admitted to the intensive care unit or high dependency unit. Fifteen patients had bacteremia, with T2Bacteria correctly identifying all on-panel (n = 8) pathogens. T2Bacteria was positive in 19 additional patients, 11 of whom had supportive cultures from other normally sterile sites (newly inserted drains, perioperative cultures or blood cultures) within seven days. Six of these eleven patients (55%) received broad-spectrum antibiotics at the sampling time. T2Candida identified the two cases of blood-culture-positive candidemia and was positive in seven additional patients, three of whom were confirmed to have intra-abdominal candidiasis. Of four patients with concurrent T2Bacteria and T2Candida positivity, only one patient had positive blood cultures (candidemia), while three out of four patients had supporting microbiological evidence of a mixed infection. T2Bacteria and T2Candida were fast and accurate in diagnosing on-panel bloodstream infections, and T2Bacteria was able to detect culture-negative intra-abdominal infections.
  •  
10.
  • Krifors, Anders, et al. (författare)
  • Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden : a prospective multicentre cohort study
  • 2024
  • Ingår i: Infectious Diseases. - : Taylor & Francis. - 2374-4235 .- 2374-4243. ; 56:2, s. 110-115
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The purpose of this study was to prospectively investigate the incidence of influenza-associated pulmonary aspergillosis (IAPA) in influenza patients admitted to intensive care units in Sweden.METHODS: The study included consecutive adult patients with PCR-verified influenza A or B in 12 Swedish intensive care units (ICUs) over four influenza seasons (2019-2023). Patients were screened using serum galactomannan and β-d-glucan tests and fungal culture of a respiratory sample at inclusion and weekly during the ICU stay. Bronchoalveolar lavage was performed if clinically feasible. IAPA was classified according to recently proposed case definitions.RESULTS: The cohort included 55 patients; 42% were female, and the median age was 59 (IQR 48-71) years. All patients had at least one galactomannan test, β-d-glucan test and respiratory culture performed. Bronchoalveolar lavage was performed in 24 (44%) of the patients. Five (9%, 95% CI 3.8% - 20.4%) patients were classified as probable IAPA, of which four lacked classical risk factors. The overall ICU mortality was significantly higher among IAPA patients than non-IAPA patients (60% vs 8%, p = 0.01).CONCLUSIONS: The study represents the first prospective investigation of IAPA incidence. The 9% incidence of IAPA confirms the increased risk of invasive pulmonary aspergillosis among influenza patients admitted to the ICU. Therefore, it appears reasonable to implement a screening protocol for the early diagnosis and treatment of IAPA in influenza patients receiving intensive care.TRIAL REGISTRATION: ClinicalTrials.gov NCT04172610, registered November 21, 2019.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 21
Typ av publikation
tidskriftsartikel (12)
bokkapitel (6)
doktorsavhandling (2)
samlingsverk (redaktörskap) (1)
Typ av innehåll
refereegranskat (18)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Krifors, Anders (13)
Mulinari, Diana (7)
Sältenberg, Hansalbi ... (7)
Neergaard, Anders (5)
Krifors, Karin (5)
Krifors, Karin, 1982 ... (4)
visa fler...
Blennow, Ola (4)
Neergaard, Anders, 1 ... (3)
Lipcsey, Miklós (3)
Castegren, Markus (3)
Athlin, Simon, 1971- (2)
Hällgren, Anita (2)
Skorup, Paul (2)
Petersson, Johan (2)
Karlsson, Linda (1)
Lundberg, Anna (1)
Larsson, Martin (1)
Johansson, Björn (1)
Svensson, Camilla (1)
Kolankiewicz, Marta (1)
Söderman, Emma (1)
Tham, Johan (1)
Winqvist, Ola (1)
Källman, Jan, 1958- (1)
Granstam, Elisabet, ... (1)
Hansson, Johan (1)
Påhlman, Lisa I. (1)
Sager, Maja (1)
Ueda, Peter (1)
Ekman, Martin (1)
Räthzel, Nora, Profe ... (1)
de Geer, Lina (1)
Hammarström, Helena (1)
Sjölin, Jan (1)
Sparrelid, Ernesto (1)
Andersson, Daniel Pe ... (1)
Özenci, Volkan (1)
Ljungquist, Oskar (1)
Wallin, Robert P. A. (1)
Janols, Helena (1)
Kinch, Amelie, 1973- (1)
Lignell, Anders (1)
Tornhill, Sofie (1)
Ljungberg, Johan (1)
Friman, Vanda, 1952 (1)
Castegren, Markus, 1 ... (1)
Eriksson, Jenny (1)
Elvstam, Olof (1)
Brodin, Daniel (1)
Tornhammar, Per (1)
visa färre...
Lärosäte
Karolinska Institutet (13)
Uppsala universitet (12)
Lunds universitet (7)
Linköpings universitet (6)
Örebro universitet (5)
Göteborgs universitet (1)
Språk
Engelska (15)
Svenska (6)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12)
Samhällsvetenskap (8)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy